摘要
目的评价莫西沙星联合卷曲霉素治疗耐多药肺结核的临床疗效。方法将86例耐多药肺结核患者随机分成观察组和对照组,每组43例,两组抗结核治疗相同的药物有力克肺疾、丙硫异烟胺、吡嗪酰胺;观察组增加莫西沙星和卷曲霉素,对照组增加左氧氟沙星和阿米卡星,对比两组痰菌阴转率、病灶吸收好转率和治愈率。结果观察组在治疗第3、6、12、18、24个月末痰菌阴转率均明显高于同期对照组;至治疗结束,观察组痰菌阴转率88.4%,对照组痰菌阴转率67.4%,观察组明显高于对照组(P<0.05),差异有统计学意义。胸部CT检查:观察组病灶吸收好转率86.1%,对照组病灶吸收好转率62.8%,观察组明显优于对照组(P<0.05),差异有统计学意义。至疗程结束,观察组治愈率83.7%,对照组治愈率58.1%,观察组明显高于对照组,两组对比差异有统计学意义(P<0.05)。结论莫西沙星联合卷曲霉素能明显提高耐多药肺结核的痰菌阴转率及病灶吸收好转率,显著提高治愈率,有效且安全,值得推广。
Objective To evaluate moxifloxacin combined capreomycin clinical efficacy for treatment of multi-drug resistant tuberculosis. Methods 86 patients diagnosed with multidrug-resistant tuberculosis were randomly divided into observation group and control group, each group with 43 cases, give the same drugs including dipasic, protionamide, pyrazinamide, observation group increased moxifloxaein and capreomycin, while levofloxacin and amikacin increased in the control group, compared to sputum conversion rates, the lesions improved absorption rate and cure rate of the two groups. Results Observed in the treatment group at the end of the 3, 6, 12,18, 24 months sputum conversion rate was significantly higher than the control group; until the end of treatment , the observation group sputum conversion rate 88.4% in the control group sputum conversion rate of 67.4% in the observation group was significantly higher （ P 〈 0.05 ） , the difference was statistically significant. Chest CT： Observer Group lesions improved absorption rate 86.1% , while 62.8% in the control group, the observation group ,was better than the control group （ P 〈 0.05 ） , the difference was statistically significant. Cure rate was 83. 7% in observation group; the control group was 58. 1%. The observation group was significantly higher than the control group, the difference between two groups was statistically significant （ P 〈 0.05 ）. Conclusions Moxifloxacin combined capreomycin treatment programs can significantly improve sputum conversion rate and the lesions improved absorption rate in muhi-drug resistant tuberculosis, significantly improve the cure rate , effective and safe , is worth of promotion.
出处
《中华肺部疾病杂志（电子版）》
CAS
2014年第3期30-33,共4页
Chinese Journal of Lung Diseases(Electronic Edition)
基金
广西壮族自治区卫生厅科研资助项目(Z2012376)
关键词
耐多药肺结核
莫西沙星
卷曲霉素
临床疗效
Multidrug- resistant tuberculosis
Moxifloxacin
Capreomycin
Clinical efficacy
